Biomarker validation: Methods and matrix matter
Alzheimers Dement
.
2017 May;13(5):608-609.
doi: 10.1016/j.jalz.2016.11.004.
Epub 2016 Dec 21.
Authors
Mark Mapstone
1
,
Amrita K Cheema
2
,
Xiaogang Zhong
3
,
Massimo S Fiandaca
4
,
Howard J Federoff
5
Affiliations
1
Department of Neurology, University of California, Irvine, Irvine, CA, USA. Electronic address: mark.mapstone@uci.edu.
2
Department of Biochemistry and Department of Oncology, Georgetown University, Washington, DC, USA.
3
Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC, USA.
4
Department of Neurology and Department of Neurological Surgery, University of California, Irvine, Irvine, CA, USA.
5
Department of Neurology, University of California, Irvine, Irvine, CA, USA.
PMID:
28010950
DOI:
10.1016/j.jalz.2016.11.004
No abstract available
Publication types
Letter
Comment
MeSH terms
Alzheimer Disease*
Biomarkers
Humans
Substances
Biomarkers
Grants and funding
R01 AG030753/AG/NIA NIH HHS/United States